Novartis Warned About Facebook Widget

September 2010
Pharmaceutical Representative;Sep2010, Vol. 40 Issue 9, p8
The article reports that Novartis AG has been warned by the U.S. Food and Drug Administration (FDA) about Facebook widget.


Related Articles

  • DDMAC warns Novartis on edu websites. Comer, Ben // Medical Marketing & Media;Jun2010, Vol. 45 Issue 6, p23 

    The article reports on the move of Food and Drug Administration's (FDA) Division of Drug Marketing, Advertising and Communications (DDMAC) to partner with Novartis AG for school awareness program and other brand promotion in the U.S.

  • Novartis' lung cancer ALK inhibitor approved. Guha, Malini // Nature Biotechnology;Jul2014, Vol. 32 Issue 7, p607 

    The article focuses on the approval made by the U.S. Food and Drug Administration (FDA) for the clinical trial of the drug Zykadia for the treatment of lung cancer by the pharmaceutical company Novartis.

  • Sandoz Bid for First U.S. Biosimilar Under Review.  // Chain Drug Review;8/11/2014, Vol. 36 Issue 12, p61 

    The article reports that the U.S. Food and Drug Administration is reviewing the application of the Swiss drug manufacturer Novartis AG to sell a biosimilar drug version of Neupogen from Amgen Inc. through its generic division Sandoz.

  • New indication supports pediatric use of Gleevec.  // Drug Topics;6/2/2003, Vol. 147 Issue 11, p5 

    Reports on the Food and Drug Administration's approval for the drug imatinib from Norvatis in Philadelphia, Pennsylvania. Test on the efficacy and safety of the drug; Indications of imatinib.

  • Alcon, Novartis seek to recover stolen products.  // Ophthalmology Times;9/1/2011, Vol. 36 Issue 17, p6 

    The article reports that Novartis AG and its Alcon division are working with the Food and Drug Administration (FDA), industry cargo thefts organizations, and law enforcement officials to recover products of Novartis that were stolen whole being delivered to a customer's distribution in Florida.

  • First artemisinin-based antimalarial combination approved for U.S. market. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;5/15/2009, Vol. 66 Issue 10, p880 

    The article reports on the move of the U.S. Food and Drug Administration (FDA) to approve the commercialization of Coartem, a treatment of acute and uncomplicated malaria infections from Novartis AG. It mentions that the drug contains 20 milligrams of artemether and 120 milligrams of...

  • Topical briefs.  // Dermatology Times;Apr99, Vol. 20 Issue 4, p4 

    Reports on developments related to dermatology in the United States as of April 1999. Includes US Food and Drug Administration's approval of an Rx-to-OTC schedule change for Novartis' Lamisil antifungal cream; FDA approval of Therakos' Uvadex steril solution 20 mcg/mL; FDA approval of...

  • 'THE FUTURE OF CANCER TREATMENT' O'Keefe, Brian // Fortune;7/23/2001, Vol. 144 Issue 2, p80 

    Discusses the outlook for the treatment of cancer. Outlook for the success of Novartis in fighting cancer, in light of the approval of the drug Gleevec; Outlook for the development of drugs to fight the disease; Approval of drugs by the United States Food and Drug Administration.

  • Pharma: Other News To Note.  // BioWorld Today;11/26/2012, Vol. 23 Issue 228, p5 

    The article reports that the U.S. Food and drug Administration (FDA) has granted Novartis AG clearance for marketing of its vaccine Flucelvax in the U.S.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics